👋 Hey, let’s get into it. You’ve probably questioned the supply chain behind a $6 spicy tuna roll at your local gas station. Turns out, your compounded GLP-1 supplier deserves that same energy.

Bloomberg reported black mold on equipment and bugs in the ceilings at a Chinese factory making ingredients for compounded GLP-1s. Inspectors also caught staff hiding paperwork and pouring product samples down sinks. At another supplier, workers reportedly approved ingredients from outside factories without reviewing their testing records. Both suppliers landed on the FDA’s import-alert list.

That gas station sushi doesn’t sound so bad after all, does it?

💰 Roche Signs $15B ADC Deal With Hansoh
Roche signed a broad Hansoh partnership covering antibody-drug conjugates, which pair antibodies with drug payloads for cancer treatment. Hansoh gets $400 million upfront, $110 million on the first anniversary, and potentially more than $15 billion in milestones, plus royalties. The portfolio includes two preclinical programs and additional Roche-proposed targets. Hansoh handles development through global Phase Ia. Roche then takes over outside mainland China, Hong Kong, Macau, and Taiwan, where Hansoh retains rights. That buys Roche multiple opportunities, with plenty of clinical work between the opening check and the biggest numbers.

🚚 Lilly’s Metis Pact Offers Up to $1.1B in Drug-Delivery Milestones
Eli Lilly partnered with Hong Kong’s Metis TechBio to help medicines reach their intended tissues. Metis uses AI to design lipid components for nanoparticles, tiny delivery vehicles carrying therapeutic cargo. The aim is better targeting, a problem that can derail even a promising payload. Metis gets an upfront payment in the low double-digit millions, with up to approximately $1.1 billion in conditional milestones, plus royalties. Even a brilliant medicine needs the right delivery address.

🤫 Germany’s Merck KGaA Agrees to Buy Silence for $1.3B
Germany’s Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value. The $20-per-ADS cash offer represents a 130% premium to Friday’s close. Merck gets an siRNA platform, which reduces production of selected proteins, and divesiran, a candidate preparing for Phase 3 in polycythemia vera, a blood cancer involving excess red-cell production. The appeal includes both a near-term development opportunity and technology for building more medicines. Closing is expected in early 2027. Apparently, buying Silence requires a fairly loud offer.

🤖 AstraZeneca Signs $1.46B AI Drug Discovery Deal With insitro
AstraZeneca is paying insitro $40 million upfront to find drug targets and candidates for MASH and cardiomyopathies. insitro’s platform combines human and cellular data with AI to untangle the biology behind those diagnoses. AstraZeneca takes over clinical development, regulatory work, and commercialization, with approximately $1.46 billion in potential milestones and royalties also available. The attraction is choosing better targets before expensive trials begin. AI can help nominate the suspect, but the experiments still have to make the case.

💊 Lilly’s Oral GLP-1 Gets EU Panel Backing
The European Medicines Agency’s committee recommended Lilly’s Foundayo GLP-1 pill for adult weight management and type 2 diabetes.

📋 FDA Starts a Rare-Disease Framework Overhaul
The FDA launched a rare-disease framework initiative focused on small population evidence, patient input, and regulatory consistency, with a public meeting scheduled for October 28.

🎟️ Ultragenyx’s FDA Voucher Sale Agreements Total $413M
Ultragenyx’s latest $203 million priority-review voucher sale agreement brings two deals to $413 million. Talk about a golden ticket.

🇪🇺 Revolution Medicines’ Rasonque Nears an EU Decision
The European Medicines Agency’s committee recommended Revolution Medicines’ Rasonque for previously treated adults with metastatic pancreatic cancer.

☀️ Disc’s Phase 3 Win Sets Up an FDA Resubmission
Disc reported bitopertin added 12.2 monthly hours of pain-free light exposure versus placebo at month six in Phase 3 for a severe light-sensitivity disorder.

🙌 AbbVie’s Crohn’s Combo Posts Higher Remission Rates
AbbVie reported its Phase 2a Crohn’s combination achieved 40.5% endoscopic remission at week 24, versus 22.4% and 20% with its components given separately.

💈 Veradermics’ Hair Loss Pill Meets Phase 3 Goals
Veradermics reported its extended-release oral minoxidil met all primary and secondary endpoints in a placebo-controlled Phase 3 study of men with pattern hair loss.

🎯 Verastem Reports a 41% Pancreatic Cancer Response Rate
Verastem reported responses in 9 of 22 previously treated pancreatic-cancer patients in Phase 1/2, positioning its KRAS G12D inhibitor as a potential rival to broader-acting Rasonque.

Pharma has been shopping China’s biotech aisle pretty enthusiastically. Now Beijing is checking what’s in the cart. A drug license? Keep browsing. Ownership of certain platforms used to invent future medicines? Beijing would like a word with your business-development team.

China’s October 16 proposal would add 40 technologies across AI, biomedicine, and photovoltaics to its export-control catalogue. Five are biomedicine-related, including specified proprietary cell and gene therapy, siRNA, and pathogen technologies. The proposed restrictions distinguish between transferring ownership of certain platforms and licensing their use. Think buying access to the recipe versus walking away with the cookbook.

That distinction leaves room for international partnerships. The ministry says licensing relevant process platforms and providing outsourced research or manufacturing services would be excluded from the proposed controls. Licenses involving certain target-discovery and validation technologies would qualify for streamlined procedures, including automatic licensing. Products manufactured using the technologies fall outside the scope described in its explanation.

But there’s already paperwork at checkout. Although public comments on the proposal run through November 15, an interim registration requirement took effect October 16. Covered technology exports must be registered before proceeding, including overseas licenses and transfers of ownership or actual control. Transactions already underway but unfinished are included. A license could therefore avoid a proposed prohibition while still requiring registration today.

For pharma deal teams, the exact technology and ownership rights matter as much as the headline price. Apparently, even a multibillion-dollar shopping spree can end with “please wait for assistance.”

This is the amount OrbiMed raised in commitments across two healthcare funds: over $1.9 billion for U.S. and European life sciences and over $1 billion for Asian healthcare. That’s future investment capital, with biotech, devices, diagnostics, and healthcare services all competing for a slice.

Here’s what biotech Redditors are talking about:

🤖 Your Boss Wants AI in Everything
Some pharma employees say their bosses want AI involved in practically everything they do, from presentations to event graphics. One commenter spent two minutes generating a deck, then 45 fixing it. Beyond the extra work, there’s another worry: use AI for every task, and you’re basically training it to do your job. Nothing says career development like being asked to onboard your potential replacement.

🦾 Will the Robots Take Over Your Lab Bench?
A scientist asked whether automated labs could make their career obsolete. A commenter identifying himself as Ginkgo’s CEO jumped in, arguing that cheaper experiments could create more demand for scientists. Others pointed to the headaches of integrating instruments and designing experiments that actually work. As for the robots, we wish them the best of luck with the temperamental plate reader and cells that only grow when Jessica feeds them at exactly 9:03am.

🎬 Elizabeth Holmes Documentary Scores a Historic Opening
Elizabeth Holmes documentary You Can See Everything opened to an estimated $15 million, the biggest non-music documentary debut in two decades. Why would I lie to you?

🪑 OpenAI Offers Eligible Labs Up to 30 Free Seats
OpenAI’s academic plan offers eligible U.S. labs up to 30 free seats for up to 12 months, with GPT-Rosalind access subject to approval.

🚨 UK Authorities Seize 12,000+ Fake GLP-1 Pens
UK authorities seized more than 12,000 counterfeit weight-loss pens in Birmingham, valued at approximately £2 million ($2.6M), plus packaging for roughly 30,000 additional products.

📈 Democrats Flag Trump’s Growing Pharma Holdings
Democrats put Trump’s maximum disclosed pharma holdings at $56.2 million in 2025, versus $1.7 million in 2024. The White House says independent managers control the investments.

🧬 Estuary Launches With $103M for Kidney Gene Therapies
Yale spinout Estuary Biotherapeutics emerged with $103 million in committed financing, including a $93 million Series A led by RA Capital. It’s developing locally delivered gene therapies for inherited polycystic kidney disease, which causes cysts and progressive kidney damage. The approach builds on mouse research showing that restoring polycystin proteins could reverse established disease. Its preclinical programs target different genetic defects: one delivers PKD2, while another supplies a functional region of polycystin-1. The first clinical study is planned for 2027. Funding is flowing toward the kidney.

October 20, 2020: ☄️ NASA Collects a Sample With Life’s Ingredients
On this day in 2020, NASA’s OSIRIS-REx briefly touched asteroid Bennu and collected rocks and dust. The sample returned to Earth in 2023, giving scientists material to investigate the chemistry that preceded life. Analyses announced in January 2025 identified 14 of the 20 amino acids used in terrestrial proteins and all five DNA/RNA nucleobases. Those familiar ingredients offer clues about how prebiotic chemistry could develop beyond Earth. They also provide fresh material for your crazy uncle’s theory that ancient aliens visited Earth and, for reasons still unclear, his house specifically.

Thinking back to the story about bosses pushing AI into everything, here’s an idea to impress your AI-obsessed boss: tell them you’ve automated your entire morning.

AI chooses when you wake up, picks your outfit, and plans breakfast to optimize your physique. Then you kiss your spouse goodbye and head to work.

Did you mention your spouse is also a chatbot? 😘🤖

You’re expecting a promotion. Your spouse says you deserve it, though they’ve been suspiciously supportive of every idea you’ve ever had.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

Reach 2,200+ scientists, founders, investors, operators, and other professionals across biotech and pharma.

We feature one exclusive sponsor per issue. If your company offers something relevant to our readers, reply to this email and let’s talk.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead